• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Antidepressant use in people with both physical health problems and depression
Many people with diseases such as cancer or diabetes or those who have had a heart attack or stroke also suffer from depression. How effective are antidepressants for these patients? And are they just as safe for these people as for those without physical health problems? Researchers from Charité - Universitätsmedizin Berlin and Aarhus University in Denmark have teamed up to investigate these questions.
Source: World Pharma News - September 8, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

500,000 missed out on blood pressure lowering drugs during pandemic
Nearly half a million people missed out on starting medication to lower their blood pressure during the COVID-19 pandemic, according to research supported by the British Heart Foundation (BHF) Data Science Centre at Health Data Research UK published today in Nature Medicine. The researchers say that thousands of people could suffer an avoidable heart attack or stroke due to delays in starting these vital medications known to stave-off deadly heart and circulatory diseases.
Source: World Pharma News - January 19, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Eating more plant-based foods may be linked to better heart health
Eating mostly plant-based foods and fewer animal-based foods may be linked to better heart health and a lower risk of dying from a heart attack, stroke or other cardiovascular disease according to new research published in the Journal of the American Heart Association, the Open Access Journal of the American Heart Association/American Stroke Association.
Source: World Pharma News - August 7, 2019 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Aspirin green light for brain bleed stroke patients, study finds
People who suffer a stroke caused by bleeding in the brain - known as brain haemorrhage - can take common medicines without raising their risk of another stroke, a major clinical trial has found. Researchers say the findings are reassuring for the thousands of people who take the medicines to reduce their risk of heart attack and another common type of stroke caused by blood clots in the brain.
Source: World Pharma News - May 23, 2019 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Amgen receives NMPA approval for Repatha ® (evolocumab) In China to reduce the risk of cardiovascular events
Amgen (NASDAQ:AMGN) announced that the National Medical Products Administration (NMPA) has approved a new indication for Repatha® (evolocumab) as the first PCSK9 inhibitor in China for adults with established atherosclerotic cardiovascular disease (ASCVD) to reduce the risk of myocardial infarction, stroke and coronary revascularization.
Source: World Pharma News - January 28, 2019 Category: Pharmaceuticals Tags: Featured Amgen Business and Industry Source Type: news

Antioxidant reduces risk for second heart attack, stroke
Doctors have long known that in the months after a heart attack or stroke, patients are more likely to have another attack or stroke. Now, a paper in the Journal of the American College of Cardiology explains what happens inside blood vessels to increase risk - and suggests a new way to treat it.
Source: World Pharma News - September 4, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

New data from landmark CVD-REAL study of patients with type-2 diabetes confirms CV benefits associated with SGLT-2 Inhibitors
AstraZeneca has announced results from a new analysis of its landmark CVD-REAL study, the first large real-world evidence study of its kind evaluating the risk of all-cause death (ACD), hospitalisation for heart failure (hHF), heart attack (myocardial infarction or MI) and stroke in patients with type-2 diabetes (T2D) receiving treatment with SGLT-2 inhibitors (SGLT-2i), including Farxiga (dapagliflozin) versus other glucose-lowering medicines.
Source: World Pharma News - March 14, 2018 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

Brilinta significantly reduces CV events and coronary death beyond one year in heart attack survivors with multi-vessel disease
AstraZeneca today announced results from a new sub-analysis of the Phase III PEGASUS-TIMI 54 trial, demonstrating a risk reduction of 19% in MACE (the composite of CV death, myocardial infarction, or stroke) (HR 0.81; 95% CI, 0.7-0.95) and of 36% in coronary death (HR 0.64; 95% CI, 0.45-0.89) from treatment with Brilinta 60mg (ticagrelor), in combination with low dose aspirin, in people who had survived a heart attack and had stenosis (abnormal narrowing) in two or more coronary blood vessels, a condition known as multi-vessel disease (MVD).
Source: World Pharma News - February 7, 2018 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

Victoza ® reduces the risk of major cardiovascular events in people with type 2 diabetes with or without prior events
A new analysis of the landmark LEADER trial shows that Victoza® (liraglutide) reduced the risk of major cardiovascular (CV) events in people with type 2 diabetes at high CV risk, irrespective of their history of having a heart attack and/or stroke or not having any of these events, when compared to placebo.(1) This post-hoc analysis was presented today at the European Society of Cardiology (ESC) Annual Congress in Barcelona, Spain.
Source: World Pharma News - August 28, 2017 Category: Pharmaceuticals Tags: Featured Novo Nordisk Business and Industry Source Type: news

Phase III COMPASS study with Bayer's rivaroxaban (Xarelto ®) shows overwhelming efficacy and meets primary endpoint early
Bayer AG and its cooperation partner Janssen Research & Development, LLC have announced that the Phase III trial COMPASS evaluating the efficacy and safety of rivaroxaban (Xarelto®) for the prevention of major adverse cardiac events (MACE) including cardiovascular death, myocardial infarction and stroke in patients with coronary artery disease (CAD) or peripheral artery disease (PAD) has met its primary endpoint ahead of time.
Source: World Pharma News - February 14, 2017 Category: Pharmaceuticals Tags: Featured Bayer Business and Industry Source Type: news

Amgen announces Repatha ® (evolocumab) significantly reduced the risk of cardiovascular events in FOURIER outcomes study
Amgen (NASDAQ:AMGN) has announced that the FOURIER trial evaluating whether Repatha® (evolocumab) reduces the risk of cardiovascular events in patients with clinically evident atherosclerotic cardiovascular disease (ASCVD) met its primary composite endpoint (cardiovascular death, non-fatal myocardial infarction (MI), non-fatal stroke, hospitalization for unstable angina or coronary revascularization) and the key secondary composite endpoint (cardiovascular death, non-fatal MI or non-fatal stroke).
Source: World Pharma News - February 3, 2017 Category: Pharmaceuticals Tags: Featured Amgen Business and Industry Source Type: news

'Mediterranean' diet linked to lower risk of heart attacks & strokes in heart patients
A "Mediterranean" diet, high in fruit, vegetables, fish and unrefined foods, is linked to a lower risk of heart attack and stroke in people who already have heart disease, according to a study of over 15,000 people in 39 countries around the world. The research also showed that eating greater amounts of healthy food was more important for these people than avoiding unhealthy foods, such as refined grains, sweets, desserts, sugared drinks and deep-fried food - a "Western" diet.
Source: World Pharma News - April 27, 2016 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Diabetes drug may prevent recurring strokes
Pioglitazone, a drug used for type 2 diabetes, may prevent recurrent stroke and heart attacks in people with insulin resistance but without diabetes. The results of the Insulin Resistance Intervention after Stroke (IRIS) trial, presented at the International Stroke Conference 2016 in Los Angeles and published in the New England Journal of Medicine, suggest a potential new method to prevent stroke and heart attack in high-risk patients who have already had one stroke or transient ischemic attack.
Source: World Pharma News - February 18, 2016 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news